Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563901 · ClinicalTrials.gov registry record
Analyzing How Genetics May Affect Response to High Blood Pressure Medications
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 37,939
- Enrollment target
NCT00563901: Completed study, sponsored by University of Alabama at Birmingham.
NCT00563901 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 37,939 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00563901 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 37,939 participants
- Enrollment target
Study Summary
High blood pressure is one of the most common health problems in the United States. There are many medications to treat high blood pressure, but there is a large variance in how people respond to these medications. It is believed that genetic variations may contribute to the inconsistent treatment response. This study will use genetic analysis to determine whether particular genes interact with high blood pressure medications to modify the risk of certain cardiovascular diseases.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37,939 participants |
| Start Date | 2000-09 |
| Est. Completion | 2004-05 |
What the finished NCT00563901 record still lists
NCT00563901 is an observational study that tracks outcomes without assigning an intervention. Its 37,939 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00563901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00563901 about?
NCT00563901 is a clinical study titled "Analyzing How Genetics May Affect Response to High Blood Pressure Medications". High blood pressure is one of the most common health problems in the United States. There are many medications to treat high blood pressure, but there is a large variance in how people respond to these medications. It is believed that genetic variations may contribute to the inconsistent treatment r...
What is the current status of trial NCT00563901?
This trial is currently completed. The enrollment target is 37,939 participants. The study started on 2000-09. Estimated completion is 2004-05.
Who is sponsoring clinical trial NCT00563901?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796505 · 37,122 participants · NA
Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement
- NCT07150923 · 36,503 participants · NA
Supraglottic Airway for Resuscitation Trial
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia